

1 **Burden of SARS-CoV-2 and protection from symptomatic second infection in children**

2 John Kubale, PhD^{1*}; Angel Balmaseda, MD^{2*}; MD, Aaron M Frutos, MPH¹; Nery Sanchez, MD^{3,4}; Miguel
3 Plazaola, MD³; Sergio Ojeda, MD^{3,4}; Saira Saborio, MS^{2,3}; Roger Lopez, MPH^{2,3}; Carlos Barilla, BA²; Gerald
4 Vasquez, BS²; Hanny Moreira, BS²; Anna Gajewski, MPH³; Lora Campredon, MPH¹; Hannah Maier, PhD¹;
5 Mahboob Chowdhury, PhD¹; Cristhiam Cerpas, BS^{2,3}; Eva Harris, PhD⁵; Guillermina Kuan, MD^{3,4}; Aubree
6 Gordon, PhD¹

7 * Authors contributed equally.

8 ¹Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA

9 ²Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

10 ³Sustainable Sciences Institute, Managua, Nicaragua

11 ⁴Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua

12 ⁵Division of Infectious Diseases and Vaccinology, School of Public Health, University of California,
13 Berkeley, Berkeley, California, USA.

14

15 **Corresponding author:** Dr. Aubree Gordon, School of Public Health, University of Michigan, Ann Arbor,

16 MI 48109; Tel. 1-734-763-3580; gordonal@umich.edu

17

18 **Word count:** 2945

19

20

21

22

23

24

25

26

27

28

29

Key Points

30 **Question:**

31 What is the burden of COVID-19 among young children and how does protection from re-infection vary
32 with age?

33 **Findings:**

34 In this study of 1964 children aged 0-14 years children <5 years had the highest rates of symptomatic
35 and severe COVID-19 while also displaying greater protection against re-infection compared to children
36 ≥10 years.

37 **Meaning:**

38 Given their greater risk of infection and severe disease compared to older children, effective vaccines
39 against COVID-19 are urgently needed for children under 5.

40

41

42 **Abstract**

43 **Importance**

44 The impact of the SARS-CoV-2 pandemic on children remains unclear. Better understanding of the
45 burden of COVID-19 among children and their protection against re-infection is crucial as they will be
46 among the last groups vaccinated.

47 **Objective**

48 To characterize the burden of COVID-19 and assess how protection from symptomatic re-infection
49 among children may vary by age.

50 **Design**

51 A prospective, community-based pediatric cohort study conducted from March 1, 2020 through October
52 15, 2021.

53 **Setting**

54 The Nicaraguan Pediatric Influenza Cohort is a community-based cohort in District 2 of Managua,
55 Nicaragua.

56 **Participants**

57 A total of 1964 children aged 0-14 years participated in the cohort. Non-immunocompromised children
58 were enrolled by random selection from a previous pediatric influenza cohort. Additional newborn
59 infants aged ≤ 4 weeks were randomly selected and enrolled monthly, via home visits.

60 **Exposures**

61 Prior COVID-19 infection as confirmed by positive anti SARS-CoV-2 antibodies (receptor binding domain
62 [RBD] and spike protein) or real time RT-PCR confirmed COVID-19 infection ≥ 60 days prior to current
63 COVID-19.

64 **Main Outcomes and Measures**

65 Symptomatic COVID-19 cases confirmed by real time RT-PCR and hospitalization within 28 days of
66 symptom onset of confirmed COVID-19 case.

67 **Results**

68 Overall, 49.8% of children tested were seropositive over the course of the study. There were also 207
69 PCR-confirmed COVID-19 cases, 12 (6.4%) of which were severe enough to require hospitalization.
70 Incidence of COVID-19 was highest among children aged < 2 years—16.1 per 100 person-years (95%
71 Confidence Interval [CI]: 12.5, 20.5)—approximately three times that of children in any other age group
72 assessed. Additionally, 41 (19.8%) symptomatic SARS-CoV-2 episodes were re-infections, with younger
73 children slightly more protected against symptomatic reinfection. Among children aged 6-59 months,
74 protection was 61% (Rate Ratio [RR]:0.39, 95% CI:0.2,0.8), while protection among children aged 5-9 and
75 10-14 years was 64% (RR:0.36,0.2,0.7), and 49% (RR:0.51,0.3-0.9), respectively.

76 **Conclusions and Relevance**

77 In this prospective community-based pediatric cohort rates of symptomatic and severe COVID-19 were
78 highest among the youngest participants, with rates stabilizing around age 5. Reinfections represent a
79 large proportion of PCR-positive cases, with children < 10 years displaying greater protection from
80 symptomatic reinfection. A vaccine for children < 5 years is urgently needed.

81

82 The SARS-CoV-2 pandemic has resulted in severe disease and death globally, particularly among the
83 elderly and immunocompromised.^{1,2} Although most pediatric SARS-CoV-2 infections are mild or
84 asymptomatic, severe illness occurs in children, including typical severe respiratory infection and multi-
85 system inflammatory syndrome (MIS-C).^{3,4} Though less common than in adults, studies have suggested
86 that younger children, older adolescents, and children with underlying health conditions more
87 frequently present with symptomatic or severe COVID-19.⁵⁻⁷ They may also be more likely to have post-
88 acute sequelae, often referred to as “long covid”, though still less likely compared to adults.^{8,9} However,
89 most of the literature regarding the burden of SARS-CoV-2 in children comes from hospital-based
90 studies, which underestimate the disease burden in children—particularly those with mild
91 infections.^{4,6,10-14} Further, what pediatric community-level evidence does exist is largely from high-
92 income countries and includes few children <5 years.¹⁵⁻¹⁷ As such, despite understanding that differences
93 in infection severity exist between adults and children, the burden and characteristics of SARS-CoV-2
94 infection among children remain poorly characterized.^{3,18}

95
96 Understanding the implications of SARS-CoV-2 for children is particularly important, as children will be
97 among the last to be vaccinated. At the time of writing, only one vaccine has been approved in the
98 United States and Europe for children under age 11¹⁹, and vaccine supplies for many countries—
99 particularly low- and middle-income countries (LMICs)—remain limited.²⁰ In fact, as of November 12,
100 2021, only 6.5% of people in low-income countries have received at least one dose.^{20,21} However, even in
101 high-income countries where older children are already being vaccinated, it is critical that we
102 understand the natural history of SARS-CoV-2 in children.

103
104 As a consensus has grown around the likelihood of SARS-CoV-2 becoming endemic, researchers have
105 begun exploring what the transition to endemicity might look like so that interventions might be tailored

106 to be more effective. The strength and durability of immune protection against SARS-CoV-2 is perhaps
107 the most important factor in this consideration. A February 2021 study by Lavine et al. suggests that
108 even though sterilizing immunity may wane quickly, if protection against severe infections remains
109 relatively stable, SARS-CoV-2 may become no more severe than the known seasonal human
110 coronaviruses.²² However, key uncertainties in the natural history of SARS-CoV-2 infection limit our
111 ability to predict whether this will occur. Of particular importance is the strength and durability of
112 immune protection against illness across the severity spectrum following natural infection in children
113 and whether the increased circulation of variants of concern has impacted the severity of COVID-19 in
114 children. These questions are also of great relevance to future emerging pathogens with pandemic
115 potential. Using data from a community-based prospective pediatric cohort in Managua, Nicaragua, we
116 aimed to assess the burden of infection and disease in the cohort, the strength of protection from
117 symptomatic re-infection, and the relative severity of symptomatic re-infections.

118 **Methods**

119 **Ethics statement**

120 The study was approved by the Institutional Review Boards of the Nicaraguan Ministry of Health
121 and the University of Michigan. Written informed consent was obtained from a parent/guardian of all
122 participants, and verbal assent was obtained from children aged ≥ 6 years.

123 **Study population and sample collection**

124 Participants were from the Nicaraguan Pediatric Influenza Cohort, the methods of which have been
125 described in detail previously.²³ Briefly, children aged 0-14 years were enrolled when visiting the Health
126 Center Sócrates Flores Vivas (HCSFV), or through home visits, and followed until their 15th birthday or
127 loss to follow-up.

128 Parents agreed to bring their children to the study clinic (HCSFV) for any illness, and all participants were
129 provided with free medical care for the duration of their participation. Initially, respiratory samples were

130 collected from participants aged 2-14 years presenting with fever/parent-reported fever and at least 1
131 of the following: cough, sore throat, or rhinorrhea, while respiratory samples were collected from
132 participants aged <2 years who presented with fever/parent-reported fever. However, in June 2020
133 these criteria were expanded so that samples were also collected from children presenting with loss of
134 taste or smell, rash, conjunctivitis, or fever without a defined focus. Samples were collected using nasal
135 and oropharyngeal flocked plastic swabs. Blood samples were obtained from children upon enrollment
136 and yearly thereafter, in February/March 2020 and February/March 2021. A subset of children had an
137 additional blood sample collected in September/October 2020.

138 **Laboratory methods**

139 RNA was extracted from respiratory samples (QIAamp Viral RNA Mini Kit, Qiagen) and tested for SARS-
140 CoV-2 via real time RT-PCR.²⁴ Blood samples were tested for antibodies against the SARS-CoV-2
141 receptor-binding domain (RBD) and spike proteins via enzyme-linked immunosorbent assay (ELISA).²⁵
142 Samples were tested for an endpoint using fourfold dilution from 100 until 6400, and the titer for each
143 sample was obtained using the Reed and Muench method.

144 **Data collection and case definitions**

145 Yearly surveys were administered at the individual and household levels every March/April, collecting
146 data on a wide variety of social and environmental factors. A SARS-CoV-2-specific survey was also
147 completed in September/October 2020 and February/March 2021. Finally, comprehensive, systematic
148 medical consult forms were collected upon each visit to the study health clinic. Data were also collected
149 at follow-up visits that were conducted until the resolution of a child's illness.

150 We classified the severity of COVID-19 as: subclinical, mild, moderate, or severe. Participants who
151 reported no symptoms associated with their infection were classified as subclinical. Those with any
152 symptoms excluding difficulty breathing, rapid breathing, or shortness of breath were classified as mild.
153 Moderate COVID-19 was considered illness with associated difficulty breathing, rapid breathing, or

154 shortness of breath. Finally, those requiring hospitalization were classified as having severe COVID-19. A
155 more detailed description of the case definitions used in this analysis can be found in the supplementary
156 materials.

157

158 Re-infection with SARS-CoV-2 was defined as a having a positive PCR result after an ELISA-positive result
159 and/or a positive PCR occurring 60+ days after an earlier PCR-positive result. We considered PCR-
160 positive results occurring within 59 days of each other to be from the same infection. For ELISA-positive
161 participants who were not positive by PCR, we utilized surveys conducted in October/November 2020
162 and February/March 2021 to retrospectively assess COVID-19 illness severity. We observed almost no
163 transmission of influenza or RSV during periods of elevated SARS-CoV-2 transmission, thus participants
164 reporting symptoms that fell within these time periods were assumed to be related to SARS-CoV-2.

165 Participants reporting symptoms between August 1, 2020-February 15, 2021, were considered not SARS-
166 CoV-2-related unless there was a clear epidemiologic link (e.g., confirmed infection in the household at
167 the same time).

168 **Statistical analysis**

169 We calculated incidence rates for COVID-19 and COVID-19 associated hospitalization using a Poisson
170 distribution to estimate 95% confidence intervals.^{26,27} Protection following SARS-CoV-2 infection was
171 calculated for those with blood samples collected in October 2020 or later. Participants were considered
172 “seropositive” starting the day their first ELISA-positive sample was collected. They were assumed to
173 remain seropositive unless they had a subsequent sample that tested negative by ELISA. We estimated
174 the protection from symptomatic re-infection as 1-Incidence rate ratio. The incidence rate ratio was
175 obtained by fitting a generalized linear model with a Poisson distribution. All analyses were conducted
176 using R version 4.1.1.

177 **Results**

178 Between March 1, 2020, and October 15, 2021, a total of 1964 children participated in the study,
179 contributing a total of 2733.6 person years, an average of 1.4 years per person (Table 1). One hundred
180 and fifty-nine (8.1%) children withdrew from the study or were lost to follow-up. The most common
181 reasons for early withdrawal were failure to appear for their yearly annual sample (44.0%) and inability
182 to find the participant at home (27.7%). Participants recorded 9804 visits to the health center with 1497
183 (76.2%) children having at least one visit. In all, 1014 (51.6%) participants were infected with SARS-CoV-
184 2 as determined by PCR or ELISA over the course of the study the study.

185 **Incidence of PCR-confirmed COVID-19**

186 Between March 1, 2020, and October 15, 2021, there were a total of 207 PCR-confirmed COVID-19 cases
187 that occurred in 201 (10.2%) participants (Table 2, Figure 1A). While low-level transmission occurred
188 throughout the study, most cases occurred in two distinct waves: March-August 2020 and April-October
189 2021 (Figure 1A). The overall incidence rate of COVID-19 in the cohort was 7.7 cases per 100 person-
190 years (95% Confidence Interval [CI]: 6.6, 8.8). When examined by age, children <2 years had the greatest
191 incidence of COVID-19, with 16.1 cases per 100 person-years (95% CI: 12.5, 20.5) (Table 2, Figure 1B).
192 Above age 2, the incidence of COVID-19 was substantially lower, but relatively stable, with rates of 5.5
193 (95% CI: 3.7, 7.9), 5.8 (95% CI: 4.3, 7.6), and 6.9 (95% CI: 5.3, 8.9) cases per 100 person-years among children
194 aged 2-4, 5-9, and 10-14 years, respectively (Table 2, Figure 1B). Female participants had a slightly
195 higher incidence of COVID-19 when compared to males; however, the difference was not significant
196 (Table 2).

197 **ELISA-confirmed symptomatic SARS-CoV-2 infection**

198 ELISA results for anti-SARS-CoV-2 antibodies were obtained for 1824 (92.9%) of participants, with 908
199 (49.8%) being seropositive over the course of the study. Antibody titers were obtained from 877 (96.6%)
200 of seropositive participants. Seroreversion was rare, with 11 (1.2%) previously seropositive participants
201 subsequently testing negative by ELISA. Of these, 10 (90.9%) were >5 years of age, while 1 was <6

202 months, suggesting that this represented a loss of maternal antibodies. Additionally, among children
203 who seroreverted, only 2 had had illness episodes that were symptomatic (both were mild)—the rest
204 were subclinical. Titers were highest among young children, decreasing between 4-6 years of age before
205 reaching a plateau where they remained relatively stable (Figure 2A). We also saw evidence of relatively
206 rapid waning of maternal antibodies among young infants, with titers steadily decreasing in the first 4
207 months of life before beginning to increase again (Figure 2B). We observed no meaningful difference in
208 titers by sex (Supplemental Figure 1).

209 **COVID-19 severity**

210 Among PCR-confirmed COVID-19 cases, 12 (5.8%) required hospitalization, resulting in an incidence rate
211 of 0.4 (95% CI: 0.2, 0.8) per 100 person years (Supplemental Table 1). Children aged <2 years had the
212 highest rate of hospitalization associated with COVID-19—2.8 times that of children aged 2-4 years
213 and 8.5 times that of children aged 5-9 years (Supplemental Table 1, Supplemental Figure 2A). We did
214 not observe any children aged 10-14 years with COVID-19 who required hospitalization.

215 **Clinical presentation and long COVID**

216 Children with PCR-confirmed COVID-19 presented with a variety of symptoms, with runny nose (75%),
217 cough (71%), and fever/feverishness (67%) being the most common (Supplemental Table 2,
218 Supplemental Figure 2). While symptoms resolved within four weeks for most children with PCR-
219 confirmed infections, 21 (10.4%) participants had at least one symptom that was present ≥ 28 days after
220 symptom onset and were classified as having “long COVID”. Of these, 9 (13.6%) were <2 years, 2 (6.7%)
221 were 2-4 years old, 3 (5.8%) were 5-9 years old, and 7 (11.9%) were 10-14 years old. Most participants
222 with long COVID had upper respiratory symptoms that lasted 28 days or longer (14 with runny nose, 7
223 with cough, 3 with sore throat, and 3 with nasal congestion), while few had long-duration non-specific
224 symptoms (4 still had a fever and 5 still had a headache). One participant under 2 years old still had
225 diarrhea and another under 2 years had rapid breathing.

226 **Protection from symptomatic second SARS-CoV-2 infection**

227 Symptomatic re-infection with SARS-CoV-2 was relatively common in the cohort, with 41 (19.8%) PCR-
228 confirmed episodes occurring in children with previous SARS-CoV-2 infection detected by PCR or ELISA.
229 All second infections occurred in 2021 when variants of concern, particularly gamma and delta, began
230 actively circulating in Nicaragua.²⁸ The relative rate of symptomatic second infection followed a similar
231 pattern to that observed with all COVID-19 cases and associated severe presentations such as
232 hospitalization. Children aged 6 months to 4 years and 5-9 years displayed slightly higher protection
233 from symptomatic second infection at 61% (RR:0.39, 95% CI:0.2,0.8) and 64% (RR:0.36, 95% CI:0.2,0.7)
234 respectively, compared to 49% (RR:0.51, 95% CI:0.3,0.9) among children 10-14 years (Table 3, Figure
235 1C). Children under 6 months of age at ELISA testing were excluded from the above analysis as they may
236 still have maternal antibody present and thus are not necessarily reinfections. This is consistent with
237 what we observed with antibody titers in the first year of life with a steady decrease in titers in the first
238 six months followed by an increase from 6-12 months (Figure 2B). While moderate and severe
239 secondary cases of COVID-19 did occur, we did not detect any difference in severity between first and
240 second infections (Supplemental Table 3).

241 **Discussion**

242
243 In this analysis, we assessed the incidence and severity of SARS-CoV-2 infections, as well as protection
244 from symptomatic re-infection, within a prospective, community-based cohort of Nicaraguan children.
245 We observed high rates of infection, with 51.6% of children being infected over the course of the study.
246 While the majority of SARS-CoV-2 episodes were mild or subclinical (Supplemental Table 4), severe
247 illness requiring hospitalization did occur, particularly among children <2 years (Supplemental Table 1).
248 Symptomatic re-infection with SARS-CoV-2 was also common, with 19.8% of PCR-confirmed episodes of
249 SARS-CoV-2 being second infections. This contributed to the lower levels of protection against
250 symptomatic re-infection that we observed compared to previous studies.

251
252 Our findings regarding the relative frequency and severity of COVID-19 in children are consistent with
253 those in the literature—specifically that pediatric SARS-CoV-2 infections are common but are largely
254 mild or subclinical.⁵⁻⁷ Another study in Nicaragua reported that 37.7% of children aged <15 were
255 seropositive for SARS-CoV-2, substantially lower than the 49.8% we observed in our study.²⁹ It was,
256 however, consistent with that estimated from a previously published analysis in a household
257 transmission cohort in the same community where 56.7% of participants were infected.³⁰ While over
258 50% of the cohort were infected in the course of the study, only 207 (19.6%) cases were detected by
259 PCR. This again demonstrates that COVID-19 cases make up only a small proportion of infections in
260 children, and underscores the importance of community-based, prospective studies in accurately
261 characterizing the natural history of pediatric SARS-CoV-2 infection. Previous studies have also indicated
262 that while most children with symptomatic infections observe symptom resolution within a few weeks,
263 some children do experience sustained symptoms broadly described as “long COVID”.^{9,15} Among
264 children with symptomatic SARS-CoV-2 infection, we observed 21 (10.1%) with symptoms that were
265 present ≥ 28 days after symptom onset, a larger proportion than the 4.4% reported by Molteni et al.¹⁵
266 However, this difference can likely be attributed to their not including children aged <5 years, as the
267 youngest and oldest age groups in our study displayed the highest frequency of long-COVID. The most
268 common symptoms that persisted beyond 28 days of onset in our study also differed from previous
269 reports, with upper respiratory symptoms being the most common rather than more non-specific
270 symptoms of fatigue and headache reported by others.^{9,15}

271
272 Given the frequently mild presentation of pediatric SARS-CoV-2 infections, the relative dearth of
273 community-based cohort studies of SARS-CoV-2 infection in children has resulted in a poor
274 understanding of the protection following infection. A previous study in this same community found

275 that protection following infection was similar to that afforded by vaccines³⁰; however, this was before
276 variants of concern were widely circulating in Nicaragua and was not powered to assess protection
277 among children under 5. Here, we found that symptomatic second infections were quite common,
278 making up ~20% of all PCR-confirmed episodes of symptomatic SARS-CoV-2 infection, with children 6-59
279 months and 5-9 years displaying greater protection against symptomatic second infection (Table 3,
280 Figure 1C). Notably, some of these second infections resulted in illnesses classified as moderate or
281 severe. We were underpowered to sufficiently explore severity of second infections compared to first.
282 Given its implications for pediatric vaccination strategies, the relative severity of second SARS-CoV-2
283 infections in children should be monitored closely moving forward.²²

284
285 This study has several key strengths. First, as a prospective, community-based pediatric cohort, it
286 provides valuable insight into the burden of symptomatic SARS-CoV-2 infection within a population that
287 is likely to be among the last to be vaccinated—children in low- and middle-income countries. Second,
288 by utilizing well-established systems for sample collection/testing combined with robust data collection,
289 we were able to characterize key aspects of SARS-CoV-2 presentation and severity among children that
290 remain poorly described. Third, by incorporating serologic testing and genetic sequencing, we were able
291 to estimate the protection conferred by natural infection, in the context of variants such as gamma and
292 delta. Fourth, while durability of immune protection against SARS-CoV-2 infection following vaccination
293 is being widely studied, fewer data are available regarding the protection following natural SARS-CoV-2
294 infection—particularly among children.

295
296 This analysis does have several limitations. First, the initial serology samples were collected in
297 February/March 2020—largely before the first wave of SARS-CoV-2 infections in Nicaragua. As such, it is
298 possible that some infections, particularly milder presentations, were missed. It is likely, however, that

299 most of these infections were captured via PCR or by ELISA testing of samples collected in late 2020 and
300 early 2021. Additionally, to assess illness severity of infections detected only by ELISA, we relied on
301 retrospective surveys that may have been subject to recall bias. Fortunately, this is likely to have
302 affected only the mildest of cases as the PCR testing criteria were quite broad—particularly after being
303 expanded in June 2020. Finally, as a community-based, prospective cohort study, we were
304 underpowered to assess the burden of MIS-C and death associated with SARS-CoV-2 infection due to
305 their rarity.

306
307 Through this prospective cohort of Nicaraguan children, we were able to assess the impact of SARS-CoV-
308 2 infection on children aged 0-14 years at the community level. We observed high rates of infection,
309 with 51.6% of children having been infected with SARS-CoV-2 over the course of the study. While illness
310 was generally mild, severe illness and prolonged sequelae were observed—most often among children
311 <2 years. Finally, symptomatic re-infection was quite common, with lower protection among children
312 aged >10 years, suggesting important age-associated differences in immune protection following
313 infection.

314

315 **References**

- 316 1. O'Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity patterns
317 of SARS-CoV-2. *Nature*. 2021;590(7844):140-145.
- 318 2. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in
319 patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-
320 analysis of observational studies. *Aging Male*. 2020;23(5):1416-1424.
- 321 3. Bhuiyan MU, Stiboy E, Hassan MZ, et al. Epidemiology of COVID-19 infection in young children
322 under five years: A systematic review and meta-analysis. *Vaccine*. 2021;39(4):667-677.
- 323 4. Parcha V, Booker KS, Kalra R, et al. A retrospective cohort study of 12,306 pediatric COVID-19
324 patients in the United States. *Sci Rep*. 2021;11(1):10231.
- 325 5. Kufa T, Jassat W, Cohen C, et al. Epidemiology of SARS-CoV-2 infection and SARS-CoV-2 positive
326 hospital admissions among children in South Africa. *Influenza Other Respir Viruses*. 2021.
- 327 6. Bailey LC, Razzaghi H, Burrows EK, et al. Assessment of 135 794 Pediatric Patients Tested for
328 Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States. *JAMA Pediatr*.
329 2021;175(2):176-184.
- 330 7. Bolaños-Almeida CE, Espitia Segura OM. Clinical and Epidemiologic Analysis of COVID-19
331 Children Cases in Colombia PEDIACOVID. *Pediatr Infect Dis J*. 2021;40(1):e7-e11.
- 332 8. Smane L, Roge I, Pucuka Z, Pavare J. Clinical features of pediatric post-acute COVID-19: a
333 descriptive retrospective follow-up study. *Ital J Pediatr*. 2021;47(1):177.
- 334 9. Brackel CLH, Lap CR, Buddingh EP, et al. Pediatric long-COVID: An overlooked phenomenon?
335 *Pediatr Pulmonol*. 2021;56(8):2495-2502.
- 336 10. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in
337 Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health*. 2020;4(9):653-
338 661.
- 339 11. Loomba RS, Villarreal EG, Farias JS, Bronicki RA, Flores S. Pediatric Intensive Care Unit
340 Admissions for COVID-19: Insights Using State-Level Data. *Int J Pediatr*. 2020;2020:9680905.
- 341 12. Salako A, Odubela O, Musari-Martins T, et al. Prevalence and Presentation of Paediatric
342 Coronavirus Disease 2019 in Lagos, Nigeria. *Int J Pediatr*. 2021;2021:2185161.
- 343 13. Saleh NY, Aboelghar HM, Salem SS, et al. The severity and atypical presentations of COVID-19
344 infection in pediatrics. *BMC Pediatr*. 2021;21(1):144.
- 345 14. Somekh I, Stein M, Karakis I, Simões EAF, Somekh E. Characteristics of SARS-CoV-2 Infections in
346 Israeli Children During the Circulation of Different SARS-CoV-2 Variants. *JAMA Netw Open*.
347 2021;4(9):e2124343.
- 348 15. Molteni E, Sudre CH, Canas LS, et al. Illness duration and symptom profile in symptomatic UK
349 school-aged children tested for SARS-CoV-2. *Lancet Child Adolesc Health*. 2021;5(10):708-718.
- 350 16. Waterfield T, Watson C, Moore R, et al. Seroprevalence of SARS-CoV-2 antibodies in children: a
351 prospective multicentre cohort study. *Arch Dis Child*. 2021;106(7):680-686.
- 352 17. Watson AM, Haraldsdottir K, Biese KM, Goodavish L, Stevens B, McGuine TA. COVID-19 in US
353 Youth Soccer Athletes During Summer 2020. *J Athl Train*. 2021;56(6):542-547.
- 354 18. Wiedenmann M, Goutaki M, Keiser O, Stringhini S, Tanner M, Low N. The role of children and
355 adolescents in the SARS-CoV-2 pandemic: a rapid review. *Swiss Med Wkly*. 2021;151:w30058.
- 356 19. Pfizer B. Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19
357 Vaccine in Children 5 to 11 Years.
358 <https://www.businesswire.com/news/home/20210920005452/en/>. Updated 9/20/2021.
359 Accessed 11/7/2021.
- 360 20. Hannah Ritchie EM, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban Ortiz-Ospina,
361 Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser. Coronavirus Pandemic (COVID-
362 19). *Our World in Data*. 2020.

- 363 21. UNDP. Global Dashboard of Vaccine Equity. <https://data.undp.org/vaccine-equity/>. Published
364 2021. Accessed 11/1/2021.
- 365 22. Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-
366 19 to endemicity. *Science*. 2021;371(6530):741-745.
- 367 23. Gordon A, Kuan G, Aviles W, et al. The Nicaraguan pediatric influenza cohort study: design,
368 methods, use of technology, and compliance. *BMC Infect Dis*. 2015;15:504.
- 369 24. Chu DKW, Pan Y, Cheng SMS, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV)
370 Causing an Outbreak of Pneumonia. *Clin Chem*. 2020;66(4):549-555.
- 371 25. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2
372 seroconversion in humans. *medRxiv*. 2020.
- 373 26. Stevenson M, Nunes T, Sanchez J, et al. EpiR: An R package for the analysis of epidemiological
374 data. 2013:9-43.
- 375 27. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio
376 (SMR). *Am J Epidemiol*. 1990;131(2):373-375.
- 377 28. Maier HE, Balmaseda A, Ojeda S, et al. An immune correlate of SARS-CoV-2 infection and
378 severity of reinfections. *medRxiv*. 2021.
- 379 29. González F, Vielot NA, Sciaudone M, et al. Seroepidemiology of SARS-CoV-2 infections in an
380 urban Nicaraguan population. *medRxiv*. 2021.
- 381 30. Maier HE, Kuan G, Saborio S, et al. Clinical spectrum of SARS-CoV-2 infection and protection
382 from symptomatic re-infection. *Clin Infect Dis*. 2021.

383

384

385 **Contributions**

386 JTK led the analysis and drafted the manuscript. AB conducted the cohort study and coordinated the
387 molecular and serological testing. GK conducted the cohort study. AG is the Principal Investigator for the
388 Nicaraguan Pediatric Influenza Cohort Study and conceptualized the cohort study and analysis. AMF
389 contributed to the analysis and the drafting/revision of the manuscript. All authors contributed to the
390 manuscript and its revision and approved its submission.

391 **Data Sharing**

392 Individual-level data may be shared with outside investigators following University of Michigan IRB
393 approval. R code is available on GitHub (<https://github.com/jkubale>). Please contact Aubree Gordon
394 (gordonal@umich.edu) to arrange for data access.

395 **Conflicts of Interest**

396 Aubree Gordon serves on an RSV vaccine scientific advisory board for Janssen Pharmaceuticals and has
397 served on a COVID-19 scientific advisory board for Gilead Sciences. All other authors certify no potential
398 conflicts of interests.

399 **Acknowledgements**

400 This work was supported by the National Institute for Allergy and Infectious Diseases (NIAID) at the US
401 National Institutes of Health (grant U01AI088654 and contract HHSN272201400006C) and a grant from
402 Open Philanthropy. We would also like to thank the study participants and their families, the amazing
403 study staff, and the people of Nicaragua. Without them none of this would be possible. We would like to
404 thank Leo Poon for providing the protocol and controls for RT-PCR testing, and Florian Krammer for
405 sharing RBD and Spike constructs as well as technical advice. We are grateful to Janet Smith, Melanie
406 Ohi and their groups at the Center of Structural Biology at the UM Life Sciences Institute for producing
407 proteins and antibodies for the ELISAs.

408

409 **Tables:**

410 **Table 1: Characteristics of study participants**

411

Characteristic	N=1964
Male ^a	985 (50.2%)
Age ^b	6.9 (4.4)
Time in study (person-years) ^b	1.4 (0.4)
Water tap outside house ^a (n = 1716)	584 (34.0)
Number in household ^b (n = 1716)	7.9 (4.4)

^aN(%)
^bMean(std. dev)

412

413

414 **Table 2: Incidence of Symptomatic SARS-CoV-2**

415

Characteristic	N = 207^a	Incidence Rate per 100 person-years^b
Male	93 (44.9)	6.8 (5.6, 8.4)
Female	114 (55.1)	8.4 (7.0, 10.1)
Age		
<2 years	66 (31.9)	16.1 (12.5, 20.5)
2-4 years	30 (14.5)	5.5 (3.7,7.9)
5-9 years	52 (25.1)	5.8 (4.3,7.6)
10-14 years	59 (28.5)	6.9 (5.3,8.9)

^aN(%)
^bIncidence rate(95% Confidence Interval)

416

417

418

419

420

421

422

423

424 **Table 3: Protection from symptomatic re-infection**

Characteristic		Number of second infections (N=41) ^a	Protection ^b
Male		14 (34.1)	62% (RR: 0.38, 95% CI: 0.2,0.7)
Female		27 (65.9)	55% (RR: 0.45, 95% CI: 0.3,0.7)
Age	6-59 months	10 (24.4)	61% (RR: 0.39, 95% CI: 0.2,0.8)
	5-9 years	11 (26.8)	64% (RR: 0.36; 95% CI: 0.2,0.7)
	10-14 years	20 (48.8)	49% (RR: 0.51; 95% CI: 0.3,0.9)

^aN(%)


^bProtection calculated as 1-RR

425

426


427 **Figures:**

428 **Figure 1: A) PCR confirmed first and second cases by week over time. B) Incidence rate (per 100 person**
429 **years) of PCR-confirmed symptomatic SARS-CoV-2 by Age – 95% confidence intervals obtained using a**
430 **Poisson distribution. C) Relative risk of symptomatic infection by seropositivity status - 95% confidence**
431 **intervals obtained using a Poisson distribution.**



432

433 **Figure 2: Anti SARS-CoV-2 IgG titers by age** - Panel A shows the log IgG titers of participants by age with
434 a loess smoother and 95% confidence interval to show the overall trend. Panel B shows the exploded
435 view of log titer levels for children aged 0-12 months (the gray shaded region in panel A), with a loess
436 smoother and 95% confidence interval for trend.



437